[en] Medullary thyroid cancer (MTC) arises from parafollicular C cells secreting calcitonin. MTC occurs both as sporadic tumors and as part of specific inherited autosomal dominant syndromes in which point mutations within a discrete set of RET codons were described. Total thyroidectomy and aggressive neck dissection represents the only chance for cure in the affected patients. Therefore, all patients with thyroid nodular disease should undergo measurement of calcitonin plasma levels to allow preclinical diagnosis of the disease and early appropriate surgery ("secondary prevention"). In case of proband patient for inherited disease, all the family members should be genetically screened to detect the disease gene carriers. Patients with germline mutation would benefit either from earlier surgery at the stage of C-cell hyperplasia or microcarcinoma or prophylactic surgery (total thyroidectomy without neck dissection) (primary prevention) before the onset of any C-cells pathology. The ideal age for performance of such prophylactic surgery is determined by the genotypic features of the disease. [fr] Le cancer médullaire de la thyroïde (CMT) se développe à partir des cellules C, responsables de la sécrétion de calcitonine. Il se présente sous une forme sporadique et sous une forme génétiquement déterminée par mutations au niveau du proto-oncogène RET. Une chirurgie extensive précoce (thyroïdectomie totale et curage ganglionnaire) représente le seul espoir de guérison des patients atteints. A cette fin, le dosage systématique de la calcitonine sérique devant toute pathologie nodulaire thyroïdienne permet le diagnostic de l'affection au stade préclinique autorisant le recours à une chirurgie adéquate (prévention secondaire par chirurgie précoce). Tout cas index de cancer médullaire doit faire l'objet d'une étude génétique. En cas d'objectivation d'une mutation du RET, tous les membres de la famille doivent être dépistés génétiquement, pour permettre, en cas de positivité, soit une chirurgie précoce au stade d'hyperplasie prétumorale des cellules C. ou de micro-carcinome médullaire, soit une chirurgie prophylactique (thyroïdectomie totale sans curage ganglionnaire) à un âge variable suivant le génotype observé niais de toute façon avant l'éclosion de la pathologie des cellules C.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Meurisse, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Defechereux, Thierry ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Hamoir, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Maweja, Sylvie ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Meurisse, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
French
Title :
Le cancer medullaire de la thyroide ou, comment des marqueurs tumoraux et les outils de la genetique autorisent le deploiement de mesures preventives.
Alternative titles :
[en] Medullary thyroid cancer: how tumor markers and genetics determine preventive measures
Hazard JB, Hawk WA, Cril GJ. - Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab, 1959, 19, 152-161.
Niccoli P, Wion-Barbot N, Caron P, et al. - Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab, 1997, 82(2), 338-341.
Wion-Barbot N, Schuffenecker I, Niccoli P, et al. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families. Ann Endocrinol (Paris), 1997, 58(4), 302-308.
Cohen R, Campos JM, Salaun C, et al. - Preoperative calcitonin levels are predictive of tumor size and post-operative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs à Calcitonine (GETC). J Clin Endocrinol Metab, 2000, 85(2), 919-922.
Guliana JM, Calmettes C. - Calcitonine et peptides apparentés. Encycl Med Chir (Elsevier, Paris), Endocrinologie-Nutrition, 1992, 100002 C 10.
Niccoli P, Brunet P, Roubicek C, et al. - Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. Eur J Endocrinol, 1995, 132(1), 75-81.
Hadjadj S, Nunez S, Bohme P, et al. - Fausse élevation du taux circulant de calcitonine induite par l'omeprazole. Presse Med, 1997, 26(38), 1859.
Ponder BAJ. - Medullary carcinoma of the thyroid. In: Peckam M, Pinedo HM, Veronesi U, eds. - Oxford Textbook of Oncology. Oxford (G.B.): Oxford University Press, 1995. p. 2110-21, vol 2.
DeLellis RA, Rule AH, Spiler I, et al. - Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma. Am J Clin Pathol, 1978, 70(4), 587-594.
Rougier P, Calmettes C, Laplanche A, et al. - The value of calcitonin and carcinoembryonic antigen in the treatment and management of non familial medullary thryoid carcinoma. Cancer, 1983, 51, 855-862.
Bardot N, Calmettes C, Schuffenecker I, et al. - Pentagastrin stimulation test and early diagnosis of medullary carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab, 1994, 78, 114-120.
Henry JF, Denizot A, Puccini M, et al. - Diagnostic précoce des cancers médullaires sporadiques de la thyroïde: intérêt du dosage systématique de la calcitonine. Presse Med, 1996, 25(33), 1583-1588.
Sipple JH. - The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med, 1961, 31, 163-166.
Gorlin RJ, Sedano HO, Vickers RA, Cervenja J. - Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid: a syndrome. Cancer, 1968, 22, 293-296.
Farndon JR, Leight GS, Dilley WG. - Familial medullary thyroid carcinoma without associated endocrinopathies: a new clinical entity. Br J Surg, 1986, 73, 278-281.
Modigliani E, Proye C. - Le traitement du cancer médullaire de la thyroïde. In Visset J, Chigot JP Eds. Le traitement du cancer du corps thyroïde. Velizy-Villacoublay: Arnette, 1998, 229-256.
Brierley J, Tsang R, Simpson WJ et al. - Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid, 1996, 6, 305-310.
Wu LT, Averbuch SD, Ball DW, et al. - Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbonize. Cancer, 1994, 73, 432-436.
Hoefnagal CA, Delprat CC, Valdes Olmos, RA. - Role of 131 metaiodobenzylguanidine therapy in medullary thyroid carcinoma. J Nucl Biol Med, 1991, 35, 334-336.
Juweid M, Sharkey R, Behr T, et al. - Targeting and initial radioimmunotherapy of medullary thyroid cancer with 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res, 1995, 55(23 suppl), 5946s-5951s.
Pacini F, Fontanelli M, Fuggazola L, Elisei R, et al. Routine measurement of serum calcitonin in nodular thyroid disease allows the preoperative diagnosis of unsuspected sporadic medullary carcinoma. J Clin Endocrinol Metab, 1994, 78, 826-829.
Moley JF, De Benedetti MK. - Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg, 1999, 229, 880-888.
Komminoth P, Kunz E, Matias-Guiu X, et al. - Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer, 1995, 76, 479-489.
Conte-Devolx B, Niccoli-Sire P. - Néoplasies endocriniennes multiples de type 2. Encycl Med chir (Elsevier, Paris), Endocrinologie-Nutrition, 10-036-A-08, 1999, 6p.
Dralle H, Gimm O, Simon D, Frank-Rue K et al. - Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary carcinoma: German and Austrian experience. World J Surg, 1998, 22, 744-751.
Machens A, Gimm O, Hinze R, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab, 2001, 86, 1104-1119.
Wells SA, Skinner MA. Prophylactic thyroidectomy based on genetic testing in patients at risk fot the multiple endocrine neoplasia type 2 syndrome. Exp Clin Endocrinol Diab, 1998, 106, 29-34.